Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | NPC1 | O15118 | 4/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | CASP3 | P42574 | 1/20 | 0.50 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.50 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.50 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | ACHE | P22303 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | ESR1 | P03372 | 1/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 2/20 | 0.40 |
| ▸ | PPARA | Q07869 | 2/20 | 0.40 |
| ▸ | APAF1 | O14727 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10733330 | 0.89 | NPC1 (0.65) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL5668373 | 0.84 | KMT2A (0.64) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4275683 | 0.84 | KMT2A (0.64) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4275687 | 0.84 | KMT2A (0.64) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4619341 | 0.83 | RAB9A (0.49) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL4619336 | 0.83 | RAB9A (0.49) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL12134416 | 0.81 | ALDH1A1 (0.52) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL505972 | 0.81 | RAB9A (0.47) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL506660 | 0.81 | ALDH1A1 (0.48) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 | |
| SCHEMBL981090 | 0.81 | GAA (0.57) | KMT2ARAB9AALDH1A1NPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8404850-B2 | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors | SOUTHWEST RESEARCH INSTITUTE (US) | 2013-03-26 | — | — | US | disclosed |
| US-20090281144-A1 | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors | SOUTHWEST RESEARCH INSTITUTE (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281144-A1 | Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors | PLPBP, PNPO, ALDOA | KMT2A 407/4885RAB9A 3654/4885ALDH1A1 163/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.